Eptinezumab With Patient Education for Chronic Migraine and Medication-Overuse Headache: The Randomized, Placebo-Controlled RESOLUTION Trial - PubMed
5 hours ago
- #Clinical Trial
- #Eptinezumab
- #Chronic Migraine
- The RESOLUTION trial evaluated eptinezumab combined with a brief educational intervention (BEI) in adults with chronic migraine (CM) and medication-overuse headache (MOH).
- Eptinezumab 100 mg IV with BEI was superior to placebo with BEI in reducing monthly migraine days (MMDs) by weeks 1-4, with a mean change of -6.9 vs -3.7 (group difference -3.2, p < 0.0001).
- All key secondary endpoints, including reductions in monthly headache days and acute medication use, showed significant improvements with eptinezumab, sustained through 12 weeks.
- Safety profiles were similar between eptinezumab (41.9% TEAEs) and placebo (36.9%), with no new safety signals identified.
- The trial provides Class I evidence supporting eptinezumab with patient education as an effective treatment for reducing disease burden in CM complicated by MOH.